Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Lancet Neurol
    June 2024
  1. KAPASI A, Schneider JA
    Speculation on the transmissibility of Alzheimer's disease.
    Lancet Neurol. 2024;23:555-556.
    >> Share

    May 2024
  2. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
    Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2024;23:500-510.
    >> Share

  3. NORDBERG A
    Insights into the progression of genetic Alzheimer's disease from tau PET.
    Lancet Neurol. 2024;23:453-454.
    >> Share

    March 2024
  4. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    >> Share

  5. THE LANCET NEUROLOGY
    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.
    >> Share

    February 2024
  6. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    >> Share

  7. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.
    >> Share

  8. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.
    >> Share

    January 2024
  9. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.
    >> Share

    December 2023
  10. RANSCOMBE P
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.
    >> Share

    November 2023
  11. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    >> Share

    September 2023
  12. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    >> Share

    July 2023
  13. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    >> Share

  14. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    >> Share

    June 2023
  15. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    >> Share

  16. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    >> Share

    May 2023
  17. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    >> Share

    February 2023
  18. MEAD S, Fox NC
    Lecanemab slows Alzheimer's disease: hope and challenges.
    Lancet Neurol. 2023;22:106-108.
    >> Share

    January 2023
  19. BOERWINKLE AH, Gordon BA, Wisch J, Flores S, et al
    Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2023;22:55-65.
    >> Share

  20. FORTEA J, Quiroz YT, Ryan NS
    Lessons from Down syndrome and autosomal dominant Alzheimer's disease.
    Lancet Neurol. 2023;22:5-6.
    >> Share

    November 2022
  21. HARDY J, de Strooper B, Escott-Price V
    Diabetes and Alzheimer's disease: shared genetic susceptibility?
    Lancet Neurol. 2022;21:962-964.
    >> Share

    October 2022
  22. JACK CR JR
    Advances in Alzheimer's disease research over the past two decades.
    Lancet Neurol. 2022;21:866-869.
    >> Share

    May 2022
  23. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    >> Share

    April 2022
  24. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    >> Share

  25. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.
    >> Share

    February 2022
  26. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    >> Share

  27. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.
    >> Share

    January 2022
  28. KANTARCI K
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.
    >> Share

    December 2021
  29. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.
    >> Share

    November 2021
  30. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    >> Share

  31. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    >> Share

  32. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    >> Share

  33. DECARLI C
    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.
    >> Share

    September 2021
  34. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    >> Share

  35. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.
    >> Share

    August 2021
  36. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    >> Share

  37. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.
    >> Share

  38. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    >> Share

    July 2021
  39. THE LANCET NEUROLOGY
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.
    >> Share

  40. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    >> Share

    April 2021
  41. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    >> Share

  42. JAGUST WJ
    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.
    >> Share

    March 2021
  43. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    >> Share

    January 2021
  44. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    >> Share

  45. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.
    >> Share

  46. THE LANCET NEUROLOGY
    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.
    >> Share

    November 2020
  47. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    >> Share

  48. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.
    >> Share

    October 2020
  49. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016